Health Care & Life Sciences » Biotechnology | TG Therapeutics Inc.

TG Therapeutics Inc.

TG Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
82.82 M
Public Float
65.97 M
TG Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.1
Market Cap
$778.46 M
Shares Outstanding
90.84 M
Public Float
72.5 M

Profile

Address
2 Gansevoort Street
New York New York 10014
United States
Employees -
Website http://www.tgtherapeutics.com
Updated 07/08/2019
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H.

Financials

View All

Michael Sean Weiss
Executive Chairman, President & CEO
Daniel Hume
Independent Director